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Background: Though exact mechanisms by which β-blockers improve LV function in heart failure (HF) are unknown, improvement in myocardial 
substrate utilization has been implicated. α1, β1 and β2 blockers, associated with enhanced insulin sensitivity, may result in increased myocardial 
glucose uptake (MGU) compared to β1 blockers. Our aim was to determine whether different types of β-blocker treatment in HF were associated 
with improvement in MGU.
Methods: 27 β-blockers naive HF patients were prospectively randomized to carvedilol or metoprolol XL. Echocardiogram, cardiac PET for MGU 
with [18F] fluoro-2-deoxy-D-glucose (FDG) were performed at baseline and after 6 months of treatment.
Results: The mean age of patients was 62.5 yrs, 99.5 % were male, 48% with ischemic HF, 41% diabetes, 81% hypertension. 89 % were on Ace-inh, 
81% diuretics. Carvedilol dose at 6 months was 37.5±17.7, metoprolol XL 153.3±93.0 mg/day. After 6 months, there was a significant improvement 
in NYHA Class (p=0.02), in LVEF (26.3±7.3; 33.3±13.3, p=0.03), in BNP (538.4± 613.1; 207.64±222.9 pg/mL, p=0.03); but no significant change 
in MGU (0.0314 ± 0.0197; 0.0281± 0.0166 mL/min/g,p=ns) (Figure). There was no difference in change in MGU with carvedilol vs metoprolol XL 
groups.
Conclusion: In HF patients treated with chronic β-blockers, the improvement in LVEF was not accompanied with improvement in myocardial 
glucose uptake, and there was no significant difference in MGU between carvedilol and metoprolol XL treated groups.
